Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel in relapsedrefractory B-Cell acute lymphoblastic leukemia patients at the 2024 European Hematology Association Congress
AUTL Stock | USD 3.27 0.17 5.48% |
About 55% of Autolus Therapeutics' institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Autolus Therapeutics suggests that some traders are interested. Autolus Therapeutics' investing sentiment shows overall attitude of investors towards Autolus Therapeutics.
Autolus |
LONDON, May 14, 2024 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication
Read at benzinga.com
Autolus Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Autolus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Autolus Therapeutics Fundamental Analysis
We analyze Autolus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Autolus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Autolus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Autolus Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Autolus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Autolus Therapeutics stock to make a market-neutral strategy. Peer analysis of Autolus Therapeutics could also be used in its relative valuation, which is a method of valuing Autolus Therapeutics by comparing valuation metrics with similar companies.
Peers
Autolus Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
TERN | Terns Pharmaceuticals | 7.82 | ||||
APLS | Apellis Pharmaceuticals | 4.63 | ||||
RZLT | Rezolute | 4.18 | ||||
BOLT | Bolt Biotherapeutics | 3.02 | ||||
ABOS | Acumen Pharmaceuticals | 2.73 | ||||
INZY | Inozyme Pharma | 2.64 | ||||
CGEM | Cullinan Oncology | 2.51 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
DAWN | Day One | 1.33 | ||||
AMLX | Amylyx Pharmaceuticals | 0.00 | ||||
CELC | Celcuity LLC | 0.47 | ||||
IKNA | Ikena Oncology | 1.17 | ||||
MNOV | MediciNova | 3.37 | ||||
LYRA | Lyra Therapeutics | 5.00 |
Check out Autolus Therapeutics Hype Analysis, Autolus Therapeutics Correlation and Autolus Therapeutics Performance. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.